Company Profile

IsoPlexis Corporation is a life sciences company. The Company is engaged in building solutions to develop curative medicines and personalized therapeutics. The Company's single-cell proteomics systems reveal biological activity in small subsets of cells, allowing researchers to connect directly to in-vivo biology and develop precise and personalized therapies. Its focuses on developing applications of its platform for cancer immunology and cell and gene therapy. The Company's platform is comprised of IsoLight and IsoSpark instruments, IsoCode and CodePlex chip consumables, and IsoSpeak software. Its IsoLight and IsoSpark instruments are designed to be automated benchtop proteomic hubs. Its IsoCode chips use its technology proteomic barcoding to capture single-cell protein information. Its CodePlex chips technology is used to test multiplexed bulk proteins. The Company's IsoSpeak software provides automated data analysis and accelerated insights with a push-button user interface.

Employees

290

Sector

Advanced Medical Equipment & Technology

More about the company

23-03-22	IsoPlexis Corporation(NasdaqGS:ISO) dropped from S&P TMI Index	CI
23-03-21	Berkeley Lights Closes IsoPlexis Merger; Combined Company PhenomeX to Begin Trading on Nasdaq Wednesday	MT
23-03-21	IsoPlexis Corporation(NasdaqGM:ISO) dropped from NASDAQ Composite Index	CI
23-03-20	Berkeley Lights, Inc. completed the acquisition of IsoPlexis Corporation from a group of shareholders.	CI
23-03-16	IsoPlexis Corporation - Shareholder/Analyst Call
23-03-02	IsoPlexis Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
23-03-01	IsoPlexis Corporation Auditor Raises 'Going Concern' Doubt	CI
23-01-12	IsoPlexis Reports Lower Preliminary 2022 Revenue; Shares Down After-Hours	MT
23-01-12	IsoPlexis Corporation Provides Preliminary Revenue Guidance for the Full Year Ended December 31, 2022	CI
23-01-05	Morgan Stanley Adjusts Price Target on IsoPlexis to $1.70 From $5, Maintains Equalweight Rating	MT
22-12-22	Sector Update: Healthcare Stocks Finish Narrowly LowerThursday	MT
22-12-22	SVB Leerink Adjusts Price Target on IsoPlexis to $1.50 From $2, Maintains Market Perform Rating	MT
22-12-22	Top Premarket Gainers	MT

23-01-05	Morgan Stanley Adjusts Price Target on IsoPlexis to $1.70 From $5, Maintains Equalweight Rating	MT
22-12-22	SVB Leerink Adjusts Price Target on IsoPlexis to $1.50 From $2, Maintains Market Perform Rating	MT
22-11-11	SVB Securities Adjusts Price Target on IsoPlexis to $2.50 From $3, Maintains Market Perform Rating	MT
22-08-11	Morgan Stanley Downgrades IsoPlexis to Equalweight From Overweight; Price Target is $5	MT
22-08-11	SVB Securities Lowers IsoPlexis to Market Perform From Outperform, Price Target to $3 From $8	MT

23-03-21	Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company	PR
23-03-16	ISOPLEXIS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
23-03-09	ISOPLEXIS CORP : Other Events (form 8-K)	AQ
23-02-16	ISOPLEXIS CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
23-02-14	ISOPLEXIS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IsoPlexis Corporation - ISO	BU

22-12-22	Renteangst zet Wall Street lager
22-12-22	Wall Street zakt hard weg
22-12-22	Rode opening Wall Street nadert
22-12-22	Futures op Wall Street wijzen omlaag

Manager	Title	Age	Since
Jing Zhou CTO	Chief Tech/Sci/R&D Officer	56	2014-12-31
John H. Leamon CTO	Chief Tech/Sci/R&D Officer	-	2021-02-28
Manny Resendes AUD	Comptroller/Controller/Auditor	-	2021-11-29

IsoPlexis Corporation Stock

Stocks

ISO

US4650051067

Advanced Medical Equipment & Technology

Latest news : IsoPlexis Corporation

Analysts' recommendations: IsoPlexis Corporation

Press Releases: IsoPlexis Corporation

News in other languages: IsoPlexis Corporation

Quotes and Performance

Managers and Directors: IsoPlexis Corporation

Latest insider transactions

Medical Software & Technology Services

Company Profile

Director	Title	Age	Since
Scott Chaplin BRD	Director/Board Member	58	2023-03-20
James McClaskey BRD	Director/Board Member	48	2023-03-20

Date	Insider	Type	Main position	Quantity	% Market Cap.
3/21/23	Jason Myers	Issuer sale	Director	129,047	0.3198%
3/21/23	Jing Zhou	Issuer sale	Chief Technology Officer	260,300	0.6451%
3/21/23	Homi Homi Shamir	Issuer sale	Director	247,095	0.6124%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ISOPLEXIS CORPORATION	+2.78%	-3.59%	-	-	30.28M
VEEVA SYSTEMS INC.	+3.71%	-4.68%	-36.05%	-5.45%	30.25B
PRO MEDICUS LIMITED	-1.42%	-14.59%	-50.04%	+138.50%	11.68B
SECTRA AB	+1.76%	-3.42%	-27.38%	+57.74%	5.28B
HEARTFLOW, INC.	-1.99%	-3.05%	-	-	2.08B
OMNICELL, INC.	+2.86%	-10.62%	+45.75%	-34.09%	1.86B
GENERATE BIOMEDICINES, INC.	-3.11%	-1.18%	-	-	1.72B
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-3.12%	-3.55%	-39.08%	-	1.03B
ARBUTUS BIOPHARMA CORPORATION	-2.01%	-3.95%	+35.19%	+102.78%	865M
B-SOFT CO.,LTD.	-4.53%	-4.82%	-44.46%	-57.70%	723M
Average	-0.51%	-5.60%	-16.58%	+33.63%	6.17B
Weighted average by Cap.	+1.67%	-6.65%	-34.36%	+34.36%